Shell Asset Management Co. Has $776,000 Holdings in IQVIA Holdings Inc. $IQV

Shell Asset Management Co. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 55.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,085 shares of the medical research company’s stock after selling 5,171 shares during the period. Shell Asset Management Co.’s holdings in IQVIA were worth $776,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC boosted its position in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at about $514,000. Private Trust Co. NA increased its position in IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its stake in IQVIA by 10.5% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 7,149 shares of the medical research company’s stock worth $1,127,000 after buying an additional 681 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Citigroup reduced their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Barclays reduced their price target on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Friday, February 6th. Evercore restated an “outperform” rating and set a $225.00 price target on shares of IQVIA in a research note on Thursday, February 5th. TD Cowen raised their price objective on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $238.20.

IQVIA Price Performance

Shares of NYSE:IQV opened at $166.70 on Tuesday. The company has a current ratio of 0.75, a quick ratio of 0.70 and a debt-to-equity ratio of 2.09. The stock has a market cap of $28.39 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.61 and a beta of 1.37. The stock’s fifty day simple moving average is $221.98 and its two-hundred day simple moving average is $209.06. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the prior year, the company posted $3.12 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.